Compare Stocks: NKTR, CYTK, NUVL, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$76.45 -1.3%	$79.10	$33.17 ▼ $88.31	$9.51B	0.38	1.84 million shs	1.27 million shs
KRYS Krystal Biotech	$327.05 -1.4%	$342.73	$136.73 ▼ $382.54	$9.81B	0.53	637,713 shs	147,892 shs
NKTR Nektar Therapeutics	$75.50 +0.9%	$67.00	$22.50 ▼ $109.00	$2.53B	1.14	702,474 shs	325,858 shs
NUVL Nuvalent	$123.96	$121.11	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	-1.34%	-2.75%	-9.92%	-1.00%	+130.06%
KRYS Krystal Biotech	-1.37%	+0.70%	-10.60%	+4.63%	+137.79%
NKTR Nektar Therapeutics	+0.85%	+3.77%	+7.31%	-0.61%	+236.00%
NUVL Nuvalent	0.00%	0.00%	+0.05%	+17.81%	+65.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$76.45 -1.3%	$79.10	$33.17 ▼ $88.31	$9.51B	0.38	1.84 million shs	1.27 million shs
KRYS Krystal Biotech	$327.05 -1.4%	$342.73	$136.73 ▼ $382.54	$9.81B	0.53	637,713 shs	147,892 shs
NKTR Nektar Therapeutics	$75.50 +0.9%	$67.00	$22.50 ▼ $109.00	$2.53B	1.14	702,474 shs	325,858 shs
NUVL Nuvalent	$123.96	$121.11	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	-1.34%	-2.75%	-9.92%	-1.00%	+130.06%
KRYS Krystal Biotech	-1.37%	+0.70%	-10.60%	+4.63%	+137.79%
NKTR Nektar Therapeutics	+0.85%	+3.77%	+7.31%	-0.61%	+236.00%
NUVL Nuvalent	0.00%	0.00%	+0.05%	+17.81%	+65.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.90	Moderate Buy	$101.15	32.31% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$361.56	10.55% Upside
NKTR Nektar Therapeutics	2.75	Moderate Buy	$150.00	98.68% Upside
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside

Current Analyst Ratings Breakdown

Latest NKTR, CYTK, NUVL, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	CYTK Cytokinetics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$106.00 ➝ $112.00
8/7/2026	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$117.00 ➝ $112.00
8/7/2026	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	CYTK Cytokinetics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$105.00 ➝ $110.00
8/7/2026	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$102.00 ➝ $112.00
8/4/2026	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$378.00 ➝ $386.00
8/3/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/3/2026	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2026	NKTR Nektar Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$153.00
7/17/2026	CYTK Cytokinetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	KRYS Krystal Biotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$364.00 ➝ $396.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$67.67M	140.58	N/A	N/A	($1.39) per share	-55.00
KRYS Krystal Biotech	$440.48M	21.98	$7.19 per share	45.49	$45.92 per share	7.12
NKTR Nektar Therapeutics	$55.23M	46.19	N/A	N/A	$4.41 per share	17.12
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	N/A
KRYS Krystal Biotech	$204.83M	$7.98	40.98	35.05	N/A	54.82%	19.34%	17.65%	N/A
NKTR Nektar Therapeutics	-$164.08M	-$8.42	N/A	N/A	N/A	-284.18%	-85.40%	-39.99%	8/13/2026 (Estimated)
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	N/A

Latest NKTR, CYTK, NUVL, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	N/A	N/A	N/A	$10.43 million	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	6.66	6.66
KRYS Krystal Biotech	N/A	8.32	7.96
NKTR Nektar Therapeutics	N/A	10.21	10.21
NUVL Nuvalent	N/A	16.14	16.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
KRYS Krystal Biotech	86.29%
NKTR Nektar Therapeutics	75.88%
NUVL Nuvalent	97.26%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
KRYS Krystal Biotech	13.10%
NKTR Nektar Therapeutics	2.50%
NUVL Nuvalent	5.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
NKTR Nektar Therapeutics	220	33.79 million	32.94 million	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable

NKTR, CYTK, NUVL, and KRYS Headlines

Recent News About These Companies

Walleye Capital LLC Buys 33,917 Shares of Nuvalent, Inc. $NUVL

July 23, 2026 | marketbeat.com

Fifth Third Bancorp Acquires New Holdings in Nuvalent, Inc. $NUVL

July 22, 2026 | marketbeat.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

July 21, 2026 | globenewswire.com

Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from Analysts

July 20, 2026 | marketbeat.com

Wall Street Zen Upgrades Nuvalent (NASDAQ:NUVL) to Sell

July 18, 2026 | marketbeat.com

Nuvalent Analyst Ratings and Price Targets | NASDAQ:NUVL | Benzinga

July 17, 2026 | benzinga.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

July 16, 2026 | globenewswire.com

GSK Pays $10.6 Billion for Nuvalent to Accelerate Lung Cancer Push

July 15, 2026 | tipranks.com

Nuvalent (NASDAQ:NUVL) Hits New 52-Week High - Here's What Happened

July 14, 2026 | marketbeat.com

Nuvalent (NASDAQ:NUVL) Insider Sells 2,111 Shares

July 11, 2026 | insidertrades.com

Nuvalent (NASDAQ:NUVL) CEO Sells 30,000 Shares of Stock

July 9, 2026 | insidertrades.com

Biotech rally rests on fundamentals, M&A appetite, says ROTY's Faison

July 9, 2026 | msn.com

Alexandra Balcom Sells 11,430 Shares of Nuvalent (NASDAQ:NUVL) Stock

July 7, 2026 | insidertrades.com

Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders

July 2, 2026 | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),

June 30, 2026 | globenewswire.com

Bernstein Sticks to Its Buy Rating for Nuvalent (NUVL)

June 25, 2026 | theglobeandmail.com

NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK

June 16, 2026 | globenewswire.com

Guggenheim downgrades Nuvalent (NUVL) to a Hold

June 12, 2026 | theglobeandmail.com

Nuvalent (NUVL) was downgraded to a Hold Rating at TD Cowen

June 12, 2026 | theglobeandmail.com

Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors

June 11, 2026 | seekingalpha.com

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

...

June 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, CYTK, NUVL, and KRYS Company Descriptions

Cytokinetics NASDAQ:CYTK

$76.45 -1.04 (-1.34%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$76.81 +0.36 (+0.47%)

As of 06:39 AM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$327.05 -4.54 (-1.37%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$321.74 -5.31 (-1.62%)

As of 04:00 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Nektar Therapeutics NASDAQ:NKTR

$75.50 +0.64 (+0.85%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$74.70 -0.80 (-1.06%)

As of 05:37 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Nuvalent NASDAQ:NUVL

$123.96 0.00 (0.00%)

As of 07/16/2026

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTR, CYTK, NUVL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTR, CYTK, NUVL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTR, CYTK, NUVL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, CYTK, NUVL, and KRYS Company Descriptions

Cytokinetics NASDAQ:CYTK

Krystal Biotech NASDAQ:KRYS

Nektar Therapeutics NASDAQ:NKTR

Nuvalent NASDAQ:NUVL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTR, CYTK, NUVL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTR, CYTK, NUVL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTR, CYTK, NUVL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, CYTK, NUVL, and KRYS Company Descriptions

Cytokinetics NASDAQ:CYTK

Krystal Biotech NASDAQ:KRYS

Nektar Therapeutics NASDAQ:NKTR

Nuvalent NASDAQ:NUVL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools